Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Greco-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer.
Authors
Todd Anthony Aguilera
University of Texas Southwestern Medical Center, Dallas, TX;
Todd Anthony Aguilera , Parag Parikh , Maged Ghaly , Sarah E. Hoffe , Joseph M. Herman , Joseph Michael Caster , Dae Won Kim , James Costello , Mokenge Peter Malafa , Muhammad S. Beg , Elizabeth Charlotte Moser , Eugene Paul Kennedy , Kara Terry , Michael Kurman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04698915
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS766)
DOI
10.1200/JCO.2023.41.4_suppl.TPS766
Abstract #
TPS766
Poster Bd #
Q2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer.
First Author: Sarah E. Hoffe
Poster
2021 ASCO Annual Meeting
GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).
First Author: Sarah E. Hoffe
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): A randomized phase 3 multicenter study.
First Author: Michael J. Pishvaian
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Toxicity and efficacy of stereotactic body radiation therapy vs. intensity-modulated radiation therapy for the treatment of locally advanced pancreatic cancer in a phase 3 trial.
First Author: Karyn A. Goodman